Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.

Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO). In his new role, and as a prominent expert and accomplished clinician, Dr. Den will lea...

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that it has obtained ISO 13485:2016 certification. The certification was awarded following an audit by the UK's independent national compliance body, British St...

#CancerBuster

Now going into clinical trials for specific types of cancer, Alpha Tau’s technology shows potential for treating any solid tumor.
 

By Brian Blum  JANUARY 3, 2019, 8:00 AM

Alpha Tau is working toward commercializing its alpha radiation therapy technolog...

Cancer is the most devastating chronic disease affecting humankind. More than 1 out of 3 people in the United States will have cancer during their lifetimes, of which 30% of them will die 5 years from diagnosis [i].  As people live longer, the number of new cancer case...